RT Journal Article
SR Electronic
T1 Interpreting the ASTEROID Trial
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 937
OP 944
VO 73
IS 10
A1 Sipahi, Ilke
A1 Nicholls, Stephen J.
A1 Tuzcu, E. Murat
A1 Nissen, Steven E.
YR 2006
UL http://www.ccjm.org/content/73/10/937.abstract
AB The ASTEROID trial (JAMA 2006; 295:1556–1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.